About Renepharmaceuticals
Renepharmaceuticals is a Healthcare company based in India. Trading and manufacturing of healthcare products for renal diseases and dialysis in India. The company has 27 employees. Its Indian entity Rene Pharmaceuticals Private Limited reported revenue of ₹16.78 Cr. Renepharmaceuticals offers products and services including KETORITE and RENECAR. Its focus areas include Pharmaceuticals, Renal Care, Kidney Disease Treatments and Biotechnology.
Company details
Rene Pharmaceutical Pvt. Ltd. was established in 2013 and has been recognized as a trusted entity in the market for healthcare products, including dialysis and transplant medications. A wide range of products is traded to enhance quality of life, with rigorous quality checks conducted to ensure conformity with industry norms. The company is focused on providing medicines for renal diseases at affordable prices, while efforts are made to improve the well-being of kidney patients through reliable offerings. Overall, high compatibility and cost-effectiveness are maintained in the products supplied.
- Headquarters India
- Employees 27
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website renepharmaceuticals.in
- Legal Name Rene Pharmaceuticals Private Limited
- Date of Incorporation 17 Mar, 2016
- Jurisdiction Mumbai, Maharashtra, India
- Annual Revenue₹16.78 Cr
FY 2025 · +1% YoY
- Net Profit₹1.23 Cr
FY 2025 · 7% margin
- EBITDA₹1.75 Cr
FY 2025 · 10% margin
- Employee Count27
Associated legal entities of Renepharmaceuticals
Renepharmaceuticals operates through Rene Pharmaceuticals Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Rene Pharmaceuticals Private Limited CIN U51101MH2016PTC274524 | Active | 17 Mar 2016 | Mumbai, Maharashtra | ₹16.8 Cr | 27 | 2 | View details |
Products & Services of Renepharmaceuticals
Renepharmaceuticals offers a comprehensive portfolio of products and services, including KETORITE and RENECAR.
Alpha Ketoanalogue Tablets are provided for the management of renal conditions.
Sevelamer Carbonate Tablets are offered for controlling phosphate levels in kidney patients.
Board of directors of Rene Pharmaceuticals Private Limited (Renepharmaceuticals)
Rene Pharmaceuticals Private Limited is the primary company behind Renepharmaceuticals. The board of Rene Pharmaceuticals Private Limited currently have 2 directors; the longest-serving is Narendra Parshuram Shelar, appointed in 2016. 3 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Narendra Parshuram Shelar DIN 06803000 | Managing Director | 17 Mar 2016 | 10 yrs 7 mo | Rene Pharmaceuticals Private Limited |
| Nalamati Arun DIN 07102219 | Director | 23 Aug 2016 | 10 yrs 2 mo | Rene Pharmaceuticals Private Limited |
Financials of Renepharmaceuticals
Figures of Rene Pharmaceuticals Private Limited, the primary company behind Renepharmaceuticals, for FY 2025. Revenue was ₹16.78 Cr (+1% year on year). Net profit was ₹1.23 Cr (7% margin). EBITDA was ₹1.75 Cr (10% margin). Revenue has grown at a compounded annual rate of +8% over three years and +1% over five years.
- ₹16.78 CrRevenue · FY 2025 · +1% YoY
- ₹1.23 CrNet profit · 7% margin
- ₹1.75 CrEBITDA · 10% margin
- ₹10 LakhPaid-up capital
- 27Employees (provident fund records)
- +8%Revenue CAGR, 3 years
- +1%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Rene Pharmaceuticals Private Limited are on its company page.
Detailed financial statements for Renepharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Renepharmaceuticals
Renepharmaceuticals is headquartered in India.
Renepharmaceuticals has 27 employees.
The primary company behind Renepharmaceuticals, Rene Pharmaceuticals Private Limited, reported revenue of ₹16.78 Cr for FY 2025, up 1% year on year.
Rene Pharmaceutical Pvt. Ltd. was established in 2013 and has been recognized as a trusted entity in the market for healthcare products, including dialysis and transplant medications. A wide range of products is traded to enhance quality of life, with rigorous quality checks conducted to ensure conformity with industry norms. The company is focused on providing medicines for renal diseases at affordable prices, while efforts are made to improve the well-being of kidney patients through reliable offerings. Overall, high compatibility and cost-effectiveness are maintained in the products supplied.
Renepharmaceuticals offers KETORITE and RENECAR.
Renepharmaceuticals operates through Rene Pharmaceuticals Private Limited.
The legal entities of Renepharmaceuticals currently have 2 directors, including Narendra Parshuram Shelar, Nalamati Arun.